Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 144.0% in August

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 10,331,073 shares, an increase of 144.0% from the July 30th total of 4,234,144 shares. Based on an average daily trading volume, of 60,973,817 shares, the short-interest ratio is currently 0.2 days. Approximately 1,266.1% of the shares of the company are short sold.

Liminatus Pharma Price Performance

Shares of LIMN traded down $0.17 during mid-day trading on Friday, reaching $4.23. The company had a trading volume of 38,621 shares, compared to its average volume of 655,043. The company has a market capitalization of $4.27 million, a P/E ratio of -0.18 and a beta of 5.35. Liminatus Pharma has a twelve month low of $4.23 and a twelve month high of $154.50. The company’s 50-day moving average is $5.70 and its 200-day moving average is $9.53.

Liminatus Pharma (NASDAQ:LIMN) last announced its quarterly earnings results on Friday, August 14th. The company reported ($1.50) EPS for the quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LIMN. Wall Street Zen lowered Liminatus Pharma to a “strong sell” rating in a research note on Saturday, August 22nd. Weiss Ratings upgraded shares of Liminatus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Liminatus Pharma presently has a consensus rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.